Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02326597 · ClinicalTrials.gov registry record · NA
Decision Aid for Therapeutic Options In Sickle Cell Disease
A NA study of Sickle Cell Disease and Sickle Cell Anemia, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 134
- Enrollment target
- 1
- Study location
NCT02326597: Completed NA study of Sickle Cell Disease and Sickle Cell Anemia, sponsored by Emory University.
NCT02326597 is a NA study of Sickle Cell Disease and Sickle Cell Anemia that has completed, run by Emory University. The registered enrollment target is 134 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02326597, a NA study of Sickle Cell Disease and Sickle Cell Anemia, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 134 participants
- Enrollment target
- 1
- Study location
Study Summary
Sickle cell disease (SCD) is an inherited disorder with chronic multi-system manifestations affecting 100,000 individuals in the US, largely of minority origin and associated with substantial morbidity, premature mortality, individual suffering, healthcare costs and loss of productivity. Disease modifying treatments such as hydroxyurea, chronic blood transfusion and curative bone marrow transplantation are offered to patients based on physician preference and current practice informed by clinical trials. Decision aids are tools that could help translate evidence from these sources into practice by helping clinicians involve patients in making deliberate choices based on accessible information about the options available and their outcomes and to help them make decisions based on their values and preferences. The overarching goal of this project is to implement a web based decision aid individualized to patient characteristics to help patients with SCD achieve more accurate perception of risks and benefits of treatment options and make decisions in congruence with their values and preferences. Investigators will use a randomized controlled trial of the effectiveness of a web-based decision aid to give patients accurate information about risks and benefits of therapies that enable patients to make decisions based on their individual values and preferences.
Primary Outcome
Subjects will take an acceptability of education questionnaire which is a 8-item survey to assess the comprehension of education received for the decision aid tool. Each item will be scored on a scale from 1-4 where 1=poor, 2=fair, 3=good, and 4=excellent. Scores will be rated individually 1-4 according to each item. There is no overall total score.
Conditions Studied
Interventions
- OTHER Decision Aid Tool
- OTHER Standard Practice
Study Locations (1)
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-04-17 |
| Phase | NA |
What the finished NCT02326597 record still lists
NCT02326597 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (54% lower).
The record links to 5 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Decision Aid Tool is the first listed.
NCT02326597 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT02326597 about?
NCT02326597 is a clinical study titled "Decision Aid for Therapeutic Options In Sickle Cell Disease". Sickle cell disease (SCD) is an inherited disorder with chronic multi-system manifestations affecting 100,000 individuals in the US, largely of minority origin and associated with substantial morbidity, premature mortality, individual suffering, healthcare costs and loss of productivity. Disease mod...
What is the current status of trial NCT02326597?
This trial is currently completed. It is a NA study. The enrollment target is 134 participants. The study started on 2015-01. Estimated completion is 2017-04-17.
What conditions does trial NCT02326597 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Sickle Cell Anemia, Hemoglobin SS, Hemoglobin SC, Hemoglobin Beta Thalassemia.
What interventions are being tested in trial NCT02326597?
The interventions under investigation include: Decision Aid Tool (OTHER), Standard Practice (OTHER).
Who is sponsoring clinical trial NCT02326597?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02326597 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02326597's enrollment target sits among peer trials
134 46th of 213 higher than 168 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Cutaneous Hydration Assessment in SCD
RECRUITING · NA
-
MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease
RECRUITING · NA
-
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia